Robert W. Baird upgraded shares of Axovant Gene Therapies (NASDAQ:AXGT) from a neutral rating to an outperform rating in a report released on Monday morning, BenzingaRatingsTable reports. They currently have $13.00 target price on the stock, down from their previous target price of $16.00.
A number of other brokerages have also weighed in on AXGT. Leerink Swann started coverage on shares of Axovant Gene Therapies in a research note on Friday, June 21st. They issued an outperform rating and a $5.79 price target on the stock. JMP Securities lifted their price target on shares of Axovant Gene Therapies from $8.00 to $28.00 and gave the company an outperform rating in a research note on Thursday, June 6th. ValuEngine raised shares of Axovant Gene Therapies from a sell rating to a hold rating in a research note on Thursday, August 1st. Zacks Investment Research raised shares of Axovant Gene Therapies from a hold rating to a strong-buy rating and set a $5.50 price target on the stock in a research note on Friday, June 14th. Finally, Cowen reaffirmed a hold rating on shares of Axovant Gene Therapies in a research note on Tuesday, July 9th. Three equities research analysts have rated the stock with a hold rating and eight have assigned a buy rating to the stock. Axovant Gene Therapies presently has a consensus rating of Buy and a consensus price target of $26.79.
Shares of NASDAQ AXGT opened at $6.62 on Monday. The company has a quick ratio of 2.63, a current ratio of 1.70 and a debt-to-equity ratio of 0.60. Axovant Gene Therapies has a 52-week low of $3.81 and a 52-week high of $20.80. The firm’s 50 day moving average price is $6.68.
Axovant Gene Therapies (NASDAQ:AXGT) last announced its quarterly earnings results on Tuesday, June 11th. The company reported ($0.45) earnings per share for the quarter, beating the Zacks’ consensus estimate of ($1.70) by $1.25. As a group, equities research analysts predict that Axovant Gene Therapies will post -4.75 earnings per share for the current year.
In related news, CEO Pavan Cheruvu purchased 7,500 shares of the business’s stock in a transaction on Friday, June 14th. The shares were purchased at an average price of $5.21 per share, with a total value of $39,075.00. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Insiders own 6.60% of the company’s stock.
Hedge funds have recently made changes to their positions in the company. Tower Research Capital LLC TRC lifted its position in shares of Axovant Gene Therapies by 955.3% in the second quarter. Tower Research Capital LLC TRC now owns 4,221 shares of the company’s stock worth $27,000 after purchasing an additional 3,821 shares in the last quarter. Jane Street Group LLC lifted its position in shares of Axovant Gene Therapies by 28.8% in the second quarter. Jane Street Group LLC now owns 46,455 shares of the company’s stock worth $289,000 after purchasing an additional 10,375 shares in the last quarter. Marshall Wace LLP bought a new stake in shares of Axovant Gene Therapies in the first quarter worth $272,000. BlackRock Inc. bought a new stake in shares of Axovant Gene Therapies in the second quarter worth $1,482,000. Finally, Primecap Management Co. CA bought a new stake in shares of Axovant Gene Therapies in the first quarter worth $1,400,000.
Axovant Gene Therapies Company Profile
Axovant Gene Therapies Ltd., a clinical-stage gene therapy company, focuses on developing a pipeline of product candidates for debilitating neurological and neuromuscular diseases. The company's current pipeline of gene therapy candidates targets GM1 gangliosidosis, GM2 gangliosidosis, Parkinson's disease, oculopharyngeal muscular dystrophy, amyotrophic lateral sclerosis, and frontotemporal dementia.
Featured Article: SEC Filing
Receive News & Ratings for Axovant Gene Therapies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Axovant Gene Therapies and related companies with MarketBeat.com's FREE daily email newsletter.